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Medical Faculty and the Max-Delbrück Center, Berlin, GermanyIntroduction: Neutrophil gelatinaseassociated lipocalin (NGAL) is a widely studied biomarker of renal
tubular injury. Urinary NGAL (uNGAL) during acute kidney injury (AKI) predicts short-term adverse
outcomes. However, the long-term predictive value is unknown.
Methods: We performed a prospective observational study of 145 patients with hospital-acquired AKI
according to Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) criteria and
analyzed the long-term predictive value of uNGAL at the time of AKI. We deﬁned a composite outcome of
all-cause mortality and the development of end-stage renal disease (ESRD).
Results: In all, 61 AKI patients died and 22 developed ESRD within 6 months. The uNGAL levels were
signiﬁcantly higher in patients with poor long-term outcomes. uNGAL levels $362 mg/l (highest quartile)
and uNGAL levels between 95 and 362 mg/l (third quartile) were associated with hazard ratios of 3.7 (95%
conﬁdence interval, 2.1–6.5) and 1.9 (1.1–3.5), respectively, compared with uNGAL levels <95 mg/l (lower
quartiles). After 6 months, 67% and 43% of patients within the highest and third uNGAL quartile,
respectively, had either progressed to ESRD or died, compared to only 21% of patients with uNGAL in
the lower 2 quartiles (P < 0.001). In multivariable Cox regression analyses accounting for conventional
predictors, uNGAL was the strongest independent predictor of adverse long-term outcomes. The
association of uNGAL levels and poor long-term outcomes remained signiﬁcant in the subgroup of
107 AKI survivors discharged without requiring dialysis (P ¼ 0.002).
Discussion: These data indicate that elevated uNGAL levels at AKI diagnosis predict poor long-term
outcomes.
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1 and carries a
signiﬁcant risk of mortality2,3 and end- stage renal
disease (ESRD).4–6 Currently, AKI is classiﬁed accord-
ing to the dynamics of serum creatinine and the abso-
lute urinary output, as reﬂected by the Risk, Injury,
Failure, Loss of kidney function, and End-stage kidney
disease (RIFLE), Acute Kidney Injury Network
(AKIN), or Kidney Disease: Improving Global Outcomes
(KDIGO) Acute Kidney Injury criteria.7–14 The presencespondence: Kai M. Schmidt-Ott, Department of Nephrology,
é Berlin and Max Delbrueck Center for Molecular Medicine,
t-Rössle-Str 10, 13125Berlin,Germany.E-mail: kai.schmidt-ott@
.de
ved 11 April 2016; revised 13 July 2016; accepted 14 July
published online 24 July 2016and severity of AKI according to these criteria are
associated with poor short-term outcomes. For instance,
in a study of more than 2000 intensive care unit pa-
tients with AKI, mortality rates increased with higher
RIFLE stages, ranging from 20% in RIFLE-R to 49.5%
in RIFLE-F.15 In hospitalized patients with and without
AKI, mortality increased from 4.4% in patients without
AKI to >40% in RIFLE-F AKI.16
Current AKI classiﬁcations have limited performance
in differentiating the pathophysiology underlying
renal functional decay. Novel biomarkers of renal
tubular injury, including neutrophil gelatinase
associated lipocalin (NGAL), kidney injury molecule1
(KIM1), liver fatty-acid binding protein (L-FABP), and
interleukin-18 (IL-18), have been shown to assist
with diagnosing and risk stratifying AKI.17–23 Based onKidney International Reports (2016) 1, 114–124
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biomarkers, the 10th Acute Dialysis Quality Initiative
(ADQI) conference recommended that new biomarkers
such as NGAL be included when diagnosing and
staging AKI because of their sensitivity and prog-
nostic importance.24,25 NGAL is a 25-kDa protein
belonging to the lipocalin family. NGAL is produced in
renal epithelia in response to nephron injury. NGAL
has utility in diagnosing AKI early in various clinical
settings, such as critically ill patients in the intensive
care unit,26–30 septic patients,31,32 and patients with
AKI after contrast agent exposure33,34 and after
surgery.35–41 NGAL effectively discriminates patients
in the emergency room with intrinsic AKI from
patients with prerenal azotemia, those with chronic
kidney disease (CKD), and those with normal renal
function.21 High NGAL levels are associated with
adverse outcomes, including in-hospital mortality and
death.21 Although most studies have addressed the
utility of NGAL in predicting short-term poor clinical
outcomes in AKI,21,37,42–45 the role of NGAL in
predicting long-term outcomes is unclear. Here, we
provide evidence that high urinary NGAL (uNGAL)
levels at the time of AKI diagnosis predict long-term
adverse outcomes, including mortality and the devel-
opment of ESRD.
MATERIALS AND METHODS
Study Design and Patient Cohort
During 2008 to 2009, a total of 145 patients with
hospital-acquired AKI were enrolled in a prospec-
tive observational study to assess the utility of
uNGAL, measured at the time of AKI, to predict in-
hospital outcome and diagnosis, as previously re-
ported.46 Brieﬂy, all hospitalized patients meeting
the RIFLE criteria were eligible and were generally
enrolled at the time of nephrology consultation.
Based on diagnostic adjudications, 32 patients had
prerenal AKI and 75 patients had intrinsic AKI (the
remaining 38 patients could not be classiﬁed based
on the available clinical data).46 We assessed long-
term outcomes of death or development of ESRD
in this cohort.
Deﬁnitions
AKI was deﬁned according to creatinine-based RIFLE
criteria (either a >50% increase in serum creatinine
concentration or a >25% decrease in glomerular
ﬁltration rate compared with baseline). ESRD was
deﬁned as a sustained (>3 months) requirement of
renal replacement therapy. Follow-up of patients was
achieved using the hospital electronic database; if in-
formation was insufﬁcient, we contacted the general
practitioner or nephrologist of the patient.Kidney International Reports (2016) 1, 114–124Study Duration
We performed the observation from November 2008
until August 2012. The median follow-up period was
6 months.
Outcome
The composite outcome included new-onset ESRD and
all-cause mortality. Time to event was calculated
between the date of study inclusion (day of urinary
sampling) and the ﬁrst occurrence of an aspect of the
composite outcome (ESRD or death). We compared the
predictive value of uNGAL levels to conventional
predictors of adverse AKI outcomes (serum creatinine,
RIFLE, and AKIN stages) as well as demographic factors
and comorbidities.
uNGAL Measurements
Urinary samples were obtained, and uNGAL was
determined on stored samples (80C) using a stan-
dardized clinical platform (Abbott Architect), as re-
ported in our previous publication.46 Brieﬂy, the assay
used a chemiluminescent microparticle immunoassay
using a noncompetitive, 2-antianalyte antibody sand-
wich, which included a microparticle reagent prepared
by covalently attaching an antianalyte antibody to
paramagnetic particles and a conjugate reagent pre-
pared by labeling a second antianalyte antibody with
acridinium. The chemiluminescent signal was cali-
brated using known quantities of recombinant NGAL.
As reported earlier, coefﬁcients of variation were 3.0%
for uNGAL at a concentration of 385 ng/ml.47
Informed Consent and Ethics
The Charité University Ethics Committee approved
the study (EA3/011/08), and written informed consent
was obtained from patients at the time point of
enrollment.46
Statistical Analysis
We performed Kaplan–Meier estimation and log-rank
tests to compare mortality and ESRD incidence as
well as a composite of both endpoints in patient subsets
stratiﬁed by NGAL quartile or creatinine quartile and
by RIFLE stage visually and statistically. Cox regres-
sion analysis was used to identify predictors of adverse
outcomes including the following covariates: de-
mographic variables (age, gender), comorbidites (CKD,
hypertension, diabetes), RIFLE and AKIN classes of
AKI, creatinine at the time of AKI, and uNGAL at the
time of AKI. Univariable Cox regression was used to
identify individual signiﬁcant predictors. Signiﬁcant
predictors were then combined in a multivariable Cox
regression analysis. Backward elimination was used to
construct a ﬁnal Cox model. P values for between-
group comparisons were calculated using c2 test,115
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appropriate). A P value <0.05 was considered to be
statistically signiﬁcant. To identify the prediction
ability of uNGAL and serum creatinine regarding
occurrence of the composite outcome (ESRD and death)
within 6 months, we performed receiver operating
characteristic (ROC) analyses. Statistical analyses were
performed using SPSS 22 and R 3.1.1 software.
RESULTS
We studied 145 patients with hospital-acquired AKI
according to RIFLE criteria at the time of AKI diag-
nosis. The association of uNGAL in these patients with
a diagnosis of intrinsic AKI and with short-term in-
hospital outcomes has been previously reported.46 We
now report the results of clinical long-term follow-up
of these patients (median follow-up, 6 months;
range, <1 to 45 months). During the follow-up period,
22 patients (15.2%) developed ESRD (deﬁned as a
sustained requirement of renal replacement therapy),
and 61 patients (42.1%) died. A total of 74 patients
(51%) experienced the composite outcome of ESRD or
death.
Patients were stratiﬁed according to NGAL quartiles
at the time of AKI diagnosis. Baseline characteristics by
NGAL quartile are shown in Table 1. Age, sex, and
comorbidities were distributed similarly among NGAL
quartiles. Patients within the highest uNGAL quartile
had higher serum creatinine levels on inclusion and
higher frequencies of stage 3 AKI. Based on diagnostic
adjudications that we had reported earlier in this
cohort and consistent with the observations reported
therein,46 patients in the higher uNGAL quartiles wereTable 1. Patient characteristics according to NGAL quartile at the time o
Patient characteristics by NGAL quartile
NGAL
quartile 1
(<38 mg/l)
NG
quarti
(38--95
Mean age, yr (SD) 65.8 (13.3) 70.8 (9.9)
Female sex, n (%) 13 (36.1%) 17 (47.2
History of chronic kidney disease, n (%) 8 (22.2%) 9 (25.0
Hypertension, n (%) 30 (83.3%) 30 (83.3
Diabetes, n (%) 12 (33.3%) 10 (27.8
Median baseline creatinine (95% CI) 83.5 (71.1–95.0) 89.5 (74.0
Median serum creatinine (95% CI) 189.5 (155.0–224.0) 176.0 (164
RIFLE-F, n (%) 9 (25%) 11 (30.6
AKIN-3, n (%) 9 (25%) 11 (30.6
Prerenal AKI, n (%) 16 (44.4%) 10 (27.8
Intrinsic AKI, n (%) 7 (19.4%) 12 (33.3
Development of ESRD during follow-up, n (%) 2 (5.6%) 4 (11.1
Death during follow-up, n (%) 11 (30.6%) 12 (33.3
Death or ESRD during follow-up, n (%) 12 (33.3%) 14 (38.9
AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; CI, conﬁdence interval; ESRD, e
Injury, Failure, Loss of kidney function, and End-stage kidney disease.
Median follow-up for outcomes: 6 months.
aKruskalWallis test.
bc2 Test.
116more likely to have a diagnosis of intrinsic AKI,
whereas patients with low uNGAL values were more
likely to have prerenal AKI. We found a stepwise
increase in the frequency of the composite outcome
according to quartiles of uNGAL levels. In all, 78% of
patients with NGAL levels$362 mg/l (corresponding to
the highest quartile) experienced the composite
outcome of death or ESRD during long-term follow-up,
compared to 54.1% in the third NGAL quartile (95–362
mg/l), 38.9% in the second NGAL quartile (38–94 mg/l),
and 33.3% in the lowest NGAL quartile (<37 mg/l).
This ﬁnding indicated that NGAL levels at the time of
AKI were strongly associated with poor long-term
outcomes. These observations were in close agreement
with cutoffs deﬁned in our earlier studies.21,46
We next compared patients who developed the
composite outcome with all other patients. The 2
groups had similar demographic features, comorbid-
ities, and creatinine levels on AKI diagnosis and dis-
played similar distributions regarding AKI severity
based on creatinine criteria, as shown in Table 2. In
contrast, NGAL levels at the time of AKI diagnosis were
signiﬁcantly higher in patients who later experienced
the composite outcome (629.0 vs. 221.5 mg/l;
P ¼ 0.005). To assess the diagnostic accuracy of
uNGAL in diagnosing occurrence of the composite
outcome (ESRD or death) at 6 months, we performed
ROC analyses. The ROCarea under the curve (AUC)
for uNGAL was 0.73 (95% conﬁdence interval [CI] ¼
0.65–0.82), which was substantially higher than the
ROC-AUC for serum creatinine (0.58; 95% CI ¼ 0.48–
0.68). At a cutoff of 362 mg/l (75th percentile), uNGAL
showed a sensitivity of 44% and speciﬁcity of 87% inf AKI
AL
le 2
mg/l)
NGAL
quartile 3
(95--362 mg/l)
NGAL
quartile 4
(>362 mg/l) P value
67.3 (17.4) 66.9 (15.9) 0.664a
%) 17 (45.9%) 12 (33.3%) 0.536b
%) 12 (32.4%) 9 (25.0%) 0.779b
%) 33 (89.2%) 25 (69.4%) 0.168b
%) 13 (35.1%) 7 (19.4%) 0.452b
–96.0) 88.0 (80.0–100.0) 83.0 (72.0–100.0) 0.870a
.6–229.5) 207.0 (188.5–238.0) 216.5 (192.0–315.0) 0.061a
%) 10 (27.0%) 13 (36.1%) 0.361b
%) 10 (27.0%) 14 (38.9%) 0.272b
%) 5 (13.5%) 1 (2.8%) <0.001b
%) 25 (67.6%) 31 (86.1%) <0.001b
%) 5 (13.5%) 11 (30.6%) 0.021b
%) 17 (45.9%) 21 (58.3%) 0.065b
%) 20 (54.1%) 28 (77.8%) 0.001b
nd-stage renal disease; NGAL, neutrophil gelatinaseassociated lipocalin; RIFLE, Risk,
Kidney International Reports (2016) 1, 114–124
Table 2. Patient characteristics according to outcome
Patient characteristics by outcome Total cohort
Outcome
P valueNeither ESRD nor death Composite (ESRD or death)
Total number, n 145 71 74
Mean age, yr (SD) 67.7 (14.4) 66,9 (15.0) 68.5 (13.9) 0.585a
Female sex, n (%) 59 (40.7%) 31 (43.7%) 28 (37.8%) 0.475b
History of chronic kidney disease, n (%) 38 (26.2%) 16 (22.5%) 22 (29.7%) 0.325b
Hypertension, n (%) 118 (81.4%) 58 (81.7%) 60 (81.1%) 0.925b
Diabetes, n (%) 42 (29.0%) 21 (29.6%) 21 (28.4%) 0.874b
Median baseline creatinine (mmol/l) (95% CI) 87 (79–91) 88 (78–95) 86.5 (77–99) 0.291a
Median serum creatinine on inclusion (mmol/l) (95% CI) 202 (189–220) 188 (174–224) 205.5 (192–229) 0.284a
RIFLE stage F, n (%) 43 (29.7%) 19 (26.8%) 24 (32.4%) 0.646b
AKIN stage 3, n (%) 44 (30.3%) 19 (26.8%) 25 (33.8%) 0.506b
Median NGAL (mg/l) (95% CI) 95.4 (71.0 120,5) 56.0 (46.6–78.4) 208.1 (114.9–329.9) <0.001a
Prerenal AKI, n (%) 32 (22.1%) 21 (29.6%) 11 (14.9%) 0.033b
Intrinsic AKI, n (%) 75 (51.7%) 27 (38.0%) 48 (64.9%) 0.001b
AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; CI, conﬁdence interval; ESRD, end-stage renal disease; NGAL, neutrophil gelatinaseassociated lipocalin; RIFLE, Risk,
Injury, Failure, Loss of kidney function.
Median follow-up for outcomes: 6 months.
aMannWhitney U test.
bc2 Test.
E Singer et al.: NGAL, AKI, and Long-term Outcomes CLINICAL RESEARCHpredicting adverse long-term outcomes within the next
6 months. In comparison, serum creatinine at a cutoff
of 264 umol/l (75th percentile) had a sensitivity of 31%
and a speciﬁcity of 79%.
To compare the impact of uNGAL levels with con-
ventional predictors of poor outcomes in patients with
AKI (age, sex, comorbidities, serum creatinine, and
RIFLE or AKIN stage), we used Cox regression analyses.
Univariate analysis using candidate predictors sug-
gested that pre-existing CKD and uNGAL >362 mg/l
on AKI diagnosis were predictors of the composite
outcome. Conversely, serum creatinine on inclusion
and RIFLE or AKIN stage were not predictive of the
composite outcome.
Next, we performed multivariable Cox regression
and performed backward selection, as shown in
Table 3. uNGAL > 362 mg/l and pre-existing CKD were
independent signiﬁcant predictors of the composite
outcome. uNGAL >362 mg/l was associated with an
adjusted hazard ratio of 3.03 (95% CI ¼ 1.86–4.94).Table 3. Univariable and multivariable Cox regression analysis on the en
Prediction of composite outcome (death or ESRD)
Univariable Cox reg
Hazard ratio 95% CI
Age (per 10 yr) 1.06 0.9–1.2
Female sex 0.96 0.6–1.5
History of chronic kidney disease 1.61 0.97–2.6
Hypertension 1 0.56–1.8
Diabetes mellitus 0.94 0.57–1.5
Serum creatinine on inclusion >264 mmol/l 1.15 0.67–1.9
RIFLE class (1-3) on inclusion 1.13 0.82–1.5
AKIN class (1-3) on inclusion 1.15 0.87–1.5
uNGAL on inclusion > 362 mg/l 2.87 1.77–4.6
AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; CI ¼ conﬁdence interval; ESRD, en
neutrophil gelatinaseassociated lipocalin.
Kidney International Reports (2016) 1, 114–124KaplanMeier analyses showed that patients
within the upper 2 uNGAL quartiles had signiﬁcantly
increased occurrences of adverse long-term outcomes
compared to patients in the lower uNGAL quartiles
(P < 0.001), as shown in Figure 1. After 6 months,
67% of patients in the highest uNGAL quartile had
either progressed to ESRD or died, compared to 43%
of patients in the third uNGAL quartile, and only
21% of patients in the lower quartiles (P < 0.001).
Cox regression analyses showed that the highest
uNGAL quartile and the third uNGAL quartile were
associated with hazard ratios of 3.7 (95% CI ¼ 2.1–
6.5; P < 0.001) and 1.9 (95% CI ¼ 1.1–3.5; P < 0.05),
respectively, compared with the lower uNGAL
quartiles. In contrast, strata of creatinine levels were
not signiﬁcantly associated with the combined
endpoint (P ¼ 0.534). Therefore, high NGAL at pre-
sentation with AKI is an independent predictor of
long-term all-cause mortality and the development of
ESRD.tire cohort of AKI patients (N ¼ 145)
ression Multivariable model using signiﬁcant covariates
P value Hazard ratio 95% CI P value
5 0.493
3 0.850
7 0.065 1.77 1.06–2.96 0.028
0.993
6 0.806
5 0.614
5 0.448
1 0.335
6 <0.001 3.03 1.86–4.94 <0.001
d-stage renal disease; RIFLE, Risk, Injury, Failure, Loss of kidney function; uNGAL, urinary
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Figure 1. Cumulative incidence of the composite outcome of death or end-stage renal disease in acute kidney injury patients stratiﬁed by
neutrophil gelatinaseassociated lipocalin (NGAL) (a) and creatinine (b). The upper quartiles of NGAL, but not creatinine, are associated with
an increasing incidence of the composite outcome.
CLINICAL RESEARCH E Singer et al.: NGAL, AKI, and Long-term OutcomesSince part of the predictive ability of NGAL levels
may be assigned to its powerful prediction of poor
short-term outcomes,46 we conducted a subgroup
analysis to remove the inﬂuence of short-term out-
comes, including only patients who had survived the
AKI episode and who were discharged without a
requirement for renal replacement therapy (N ¼ 107).Table 4. Univariable and multivariable Cox regression analysis on the su
were discharged without a requirement for renal replacement therapy
Prediction of composite outcome (death or ESRD)
Univariate Cox reg
Hazard ratio 95% CI
Age (per 10 yr) 1.39 1.06–1.8
Female sex 0.84 0.42–1.6
History of chronic kidney disease 1.3 0.57–2.9
Hypertension 1.49 0.58–3.8
Diabetes mellitus 0.88 0.42–1.8
Serum creatinine on inclusion >264 mmol/l 0.66 0.26–1.7
RIFLE class (1–3) on inclusion 0.77 0.49–1.2
AKIN class (1–3) on inclusion 0.8 0.53–1.2
uNGAL on inclusion >362 mg/l 3.48 1.70–7.1
AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; CI, conﬁdence interval; ESRD, end
neutrophil gelatinaseassociated lipocalin.
118Of these patients, 5 developed ESRD and 32 died dur-
ing long-term follow up. Cox regression showed that
NGAL at the time of AKI diagnosis remained an inde-
pendent predictor of the combined endpoint in these
patients and that creatinine had no association with
long-term outcomes in these patients, as shown in
Table 4. KaplanMeier analyses for this subgroupbpopulation of patients who had survived the AKI episode and who
ression Multivariable model using signiﬁcant covariates
P value Hazard ratio 95% CI P value
3 0.019 1.42 1.09–1.85 0.010
9 0.628
8 0.534
5 0.406
2 0.728
0 0.392
2 0.259
3 0.308
2 0.001 3.93 1.90–8.13 <0.001
-stage renal disease; RIFLE, Risk, Injury, Failure, Loss of kidney function; uNGAL, urinary
Kidney International Reports (2016) 1, 114–124
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results were associated with signiﬁcantly greater haz-
ards of experiencing the composite outcome (P ¼
0.002), as shown in Figure 2. In contrast, increasing
creatinine quartiles were not signiﬁcantly associated
with outcomes in this subgroup. These data indicate
that NGAL-positive AKI predicts poor long-term out-
comes even in patients who initially recover from their
AKI episode.
The predictive ability of uNGAL regarding long-term
outcomes may be driven by the ability of uNGAL to
distinguish prerenal and intrinsic AKI. As reported in
our previous investigation,46 32 patients within our
cohort had prerenal AKI and 75 patients had
intrinsic AKI at the time of enrollment in the study
(the remaining 38 patients could not be classiﬁed based
on the available clinical data). We used KaplanMeier
analyses to compare long-term outcomes in patients
with prerenal AKI and in those with intrinsic AKI. As
shown in Figure 3, patients with intrinsic AKI pro-
gressed to ESRD or death more frequently thanFigure 2. Subgroup analysis of cumulative incidence of the composite outc
patients stratiﬁed by neutrophil gelatinaseassociated lipocalin (NGAL) (a
and who were discharged without a requirement for renal replacement th
creatinine, remain associated with an increasing incidence of the compo
Kidney International Reports (2016) 1, 114–124patients with prerenal AKI (Figure 3, P ¼ 0.003 by
log-rank test).
DISCUSSION
This study is the ﬁrst to demonstrate that uNGAL
levels measured at the time of AKI diagnosis in the
hospital are predictive of death or the development of
ESRD in the long term. Although the fact that AKI has
an important impact on patients’ long-term outcomes is
well known,17–22,48 our study shows that uNGAL is
superior to creatinine levels or AKI stage in assessing
the long-term prognosis. In addition, our study is the
ﬁrst to assess the relative predictive value of uNGAL
when compared to other predictors in the setting of
AKI. The difference in long-term outcomes may be
driven by the distinct pathophysiology of prerenal and
intrinsic AKI that is reﬂected by uNGAL levels.46
Previous studies have linked high NGAL levels with
adverse long-term outcomes in other clinical settings.
For instance, Ralib et al. showed an association of
uNGAL at the time of intensive care unit admission andome of death or end-stage renal disease in acute kidney injury (AKI)
) and creatinine (b). Only patients who had survived the AKI episode
erapy were included (N ¼ 107). The upper quartiles of NGAL, but not
site outcome.
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Figure 3. Cumulative incidence of the composite outcome of death
or end-stage renal disease in patients with intrinsic and prerenal
acute kidney injury (AKI; P ¼ 0.003 by log-rank test).
CLINICAL RESEARCH E Singer et al.: NGAL, AKI, and Long-term Outcomes1-year mortality, but did not consider the presence or
absence of an AKI diagnosis.49 Similarly, a recent long-
term follow-up analysis of the Translational Research
Investigating Biomarker Endpoints in AKI study in
patients undergoing cardiac surgery found an associa-
tion of perioperative peak uNGAL concentrations with
long-term mortality rates. Indeed, these authors
observed a stepwise increase in mortality rates by
tertile of uNGAL, irrespective of the presence or
absence of postoperative AKI.50 Srisawat et al.51
showed in their study that elevated plasma NGAL
levels in patients with AKI due to pneumonia were
associated with short-term renal nonrecovery. How-
ever, mortality as an outcome was not investigated,
and uNGAL was not measured. Another study in
critically ill patients with AKI requiring RRT52
showed that relative changes in urinary NGAL values
during the ﬁrst 2 weeks after AKI predicted recovery of
the kidney function with a ROC-AUC of 0.7. This
moderate performance may be explained by the rela-
tive short follow-up of 60 days and by the fact that
mortality was not an aspect of the study endpoint.
Plasma NGAL predicted all-cause mortality in patients
with hepatorenal syndrome.53 In patients after hep-
atobiliary surgery, uNGAL predicted worsening of the
kidney function but not mortality during 6 months of
follow-up.54 In a community-based study, uNGAL had
a strong association with ESRD and all cause mortality120in diabetic individuals at the 14-year follow-up.55
Furthermore, several studies provide evidence that
NGAL may be helpful in assessment of long-term (from
6 months up to 3 years) mortality in patients with
chronic heart failure,56,57 acute heart failure,58,59
ST-elevation myocardial infarction,60 and elective
percutaneous intervention due to stable angina pec-
toris.61 Together, these studies support a role for
uNGAL measurements in assessing long-term prognosis
and lend further plausibility to the ﬁndings reported
herein.
In our study, neither RIFLE nor AKIN stage
currently used to risk stratify patients with acute
kidney injury contributed to the prediction of long-
term mortality or ESRD. This may be due to the fact
that our study population included only patients with
established AKI and hence lacked an internal compar-
ator population without AKI. In addition, the relatively
small sample size of our study makes it difﬁcult to ﬁnd
signiﬁcant differences in long-term outcomes between
different AKI stages.
In addition, serum creatinine at AKI diagnosis dis-
played weak associations with long-term outcomes
when compared to uNGAL. Although there was a
slight increase in serum creatinine in patients groups in
increasing uNGAL quartiles (from a median of 189.5
mmol/L in the lowest quartile to a median of 216.5
mmol/L in the highest quartile; P ¼ 0.061), there was
still a large overlap of serum creatinine values between
groups in different uNGAL quartiles (see the inter-
quartile ranges of serum creatinine values in Table 1).
In fact, the correlation of uNGAL and serum creatinine
was weak (correlation coefﬁcient ¼ 0.272), as was the
correlation between uNGAL quartile and serum creat-
inine quartile (correlation coefﬁcient ¼ 0.189). This
explains why uNGAL quartiles and creatinine quartiles
showed a markedly different association with long-
term outcomes.
Other studies have clearly deﬁned the impact of AKI
on long-term outcomes, including death and ESRD. For
instance, in adult cardiac surgery patients, the presence
of AKI according to RIFLE criteria predicted 90-day
mortality with an ROC-AUC of 0.82.62 There was a
stepwise increased mortality with advancing stages of
AKI. Children undergoing cardiac surgery had a higher
4-year mortality with AKI RIFLE F than without AKI
(odds ratio ¼ 3.82, CI 1.89–7.75).63 A prospective study
on adult cardiac surgery patients demonstrated that
modiﬁed RIFLE I and F stages were independent pre-
dictors of long-term mortality (hazard ratio ¼ 2.35 and
3.09, respectively) compared to patients without AKI.64
In patients with acute myocardial infarction, AKI
severity by RIFLE classiﬁcation during the ﬁrst week
after hospitalization was an independent predictor ofKidney International Reports (2016) 1, 114–124
E Singer et al.: NGAL, AKI, and Long-term Outcomes CLINICAL RESEARCH2-year mortality (hazard ratio ¼ 8.1 and 19.3 for RIFLE
I and F respectively).65 However, these results were not
replicated in all studies. In a population-based study,
RIFLE predicted recovery of renal function, renal
replacement therapy requirement, hospital length of
stay, and in-hospital mortality, but not mortality at
90 days or 6 months.66 Also, 2-year mortality of neo-
nates undergoing cardiac surgery was not different
whether or not they developed AKI, regardless of
AKIN stage.67
Our observations also underline the importance of
distinguishing the pathophysiology of AKI to differ-
entiate intrinsic from prerenal AKI, potentially aided
by biomarkers such as uNGAL. We found that pa-
tients with an adjudicated diagnosis of intrinsic AKI
displayed signiﬁcantly more adverse long-term out-
comes with a cumulative incidence of > 60% during a
2-year follow-up. This incidence was signiﬁcantly
higher than that in patients with prerenal AKI,
stressing the importance of distinguishing between
different entities of AKI, not only for clinical man-
agement but also for prognostic assessment. Surpris-
ingly, however, long-term outcomes were also
remarkably frequent in patients who were assigned a
diagnosis of prerenal AKI, with 2-year mortality
approaching 40%. Although this may reﬂect adverse
effects of prerenal azotemia, a more likely explanation
lies in the fact that patients with prerenal AKI have
severe comorbidities that predispose them to adverse
long-term outcomes. These observations are consistent
with previous analyses showing not only that the
duration of AKI has a positive association with mor-
tality but that even transient AKI is associated with an
elevated risk of death.68
In addition, we observed that pre-existing CKD
was a signiﬁcant predictor of long-term outcomes in
our cohort. We anticipated a role for pre-existing
CKD as a predictor of long-term outcomes. Notably,
a large multicenter study69 demonstrated that patients
with AKI on CKD during hospitalization had signiﬁ-
cantly worse long-term survival over a median
follow-up of 4.8 years than patients with AKI but
without CKD.
Our study has limitations. We conducted our
analysis in a relatively small cohort at a single cen-
ter. The deﬁnition of AKI in our study relied solely
on creatinine dynamics. Urinary output was not
assessed in our study, as most of our patients had
AKI outside the intensive care unit setting. In
addition, our study was not sufﬁciently powered to
assess the individual components of the composite
endpoint (mortality and ESRD) separately. This issue
will need to be addressed in larger future cohorts. In
addition, we do not have detailed informationKidney International Reports (2016) 1, 114–124regarding the cause of death for most patients.
However, our analysis including only patients who
were alive and dialysis free on hospital discharge
indicates that even when the initial episode of crit-
ical illness is survived, patients with NGAL-positive
AKI remain at an increased risk for death or ESRD.
Hence, further studies are needed to assess the long-
term prognostic impact of uNGAL in patients with
established AKI.
Long-term management of patients with AKI is
currently suboptimal.70,71 Evidence exists that patients
who experience AKI episodes are not followed up
systematically in the health care system. This state of
affairs is concerning, especially given that multiple
potential medical interventions exist. For instance,
patients with post-AKI CKD might beneﬁt from
adequate blood pressure control,72,73 an adaptation of
glucose-lowering strategies,74 and statin therapy.75–79
The current uncertainty regarding post-AKI manage-
ment may be due in part to the wide range of outcomes
in post-AKI patients, ranging from complete restitution
of kidney function to quick progression to CKD. A
parameter that predicts adverse clinical courses in the
setting of AKI would help to prioritize patients’ follow-
up, for example by nephrologists, during patients’
hospital stay. Hence, determining uNGAL levels at the
time of AKI diagnosis, in addition to improving diag-
nostic assessment,21,46 may help in the selection of
patients who require close medical attention after their
hospital stay.
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